Beijing, Shanghai & Boston [May 13, 2026] — Jacobio Pharma (1167.HK) today announced that Dr. Yan Chen has officially joined the company as Vice President of CMC, where he will be responsible for process scale-up and optimization for the company’s pipeline programs, as well as CMC-related activities supporting product commercialization.

Dr. Chen brings 15 years of experience in CMC, with deep expertise across the CMC development process for small molecules and various new modalities. Prior to joining Jacobio, Dr. Chen was responsible for process development at Porton Pharma Solutions and held positions at BioDuro and GSK. He has led multiple projects across R&D, manufacturing, and regulatory submissions, with extensive experience in CMC system development, process development, scale-up manufacturing, and regulatory filing support.

Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma, said:

“We are very pleased to welcome Dr. Yan Chen to Jacobio. Dr. Chen brings extensive experience in CMC development for small molecules and new modalities. His joining will further strengthen the company’s CMC capabilities and accelerate the industrialization of Jacobio’s small molecule platform and xADC platform programs. We believe that as pipeline programs including our pan-KRAS inhibitors progress from early-stage clinical development into Phase II and registrational clinical trials, the need for robust CMC capabilities to support product commercialization will continue to grow.”

Dr. Yan Chen said:

“It is a great honor to join Jacobio. Boasting profound accumulated expertise in innovative oncology drug R&D, the Company continues to expand its cutting-edge technology platforms covering small molecules, xADC and other novel modalities. I am looking forward to working closely with all team members to further elevate the efficiency and quality of CMC development, and to accelerate the advancement of the Company’s innovative pipelines toward registrational clinical trials and eventual commercialization.”

Jacobio will continue to strengthen its end-to-end capabilities across discovery, clinical development, and regulatory submission, supporting the continued development of its globally competitive innovative pipeline, small molecule platform, and xADC platform.

About Jacobio

Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R & D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R & D center in Boston, USA, to strengthen and coordinate the global development of new drugs.